Table 3.
Univariable and multivariable analyses for OS
| Label | Modality | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| IPI | 3-5 | 2.9 | 1.3 to 6.4 | .0063 | |||
| TMTV | >220 | 3.3 | 1.8 to 6.2 | <.0001 | 3.1 | 1.6-5.7 | .0005 |
| Treatment arm | Lenalidomide | 1.0 | 0.6 to 1.7 | .90 | 1.2 | 0.7-2.0 | .5 |
| NCCN-IPI score | High-intermediate | 3.3 | 1.3 to 8.3 | .0097 | |||
| High | 2.3 | 1.1 to 4.9 | .0359 | ||||
| ECOG PS | ≥2 | 2.5 | 1.4 to 4.4 | .0011 | 2.2 | 1.3-4.0 | .0066 |
| Ann Arbor stage | III-IV | 2.9 | 0.7 to 12.0 | .14 | |||
| LDH level | Elevated | 1.3 | 0.8 to 2.3 | .31 | |||
| β2 microglobulin | ≥3 mg/L | 1.3 | 0.7 to 2.3 | .45 | |||
| Albumin | >35 g/L | 0.5 | 0.3 to 0.9 | .01 | |||
| Time to treatment (days) | 1.0 | 0.99 to 1.0 | .61 | ||||